World Contraception Day 2015 :
Bayer Supports the Wellbeing of Farmers in Sragen through Family Planning and Reproductive Health
As a Life Science Company and as a market leader for oral contraceptive in Indonesia, Bayer fully support the Indonesian government's program and effort in revitalizing family planning in the country.
- Dialogue interactive about Family Planning and Family Planing Services.
- Bayer Indonesia collaborates with the Indonesian Midwives Association Sragen branch and the Indonesian Family Planning Instructors of Sragen to conduct a program called Family Planning Ambassadors for a healthy and prosperous Sragen.
Sragen has one of the best economic growth potential in the country and the majority of its people are farmers. A crucial factor that determines the wellbeing of any family is the state of their overall health, which includes reproductive health and the use of contraception. As the income of farmers in Sragen grow, it is important that they have proper access, information and education on family planning and reproductive health. Bayer Indonesia remains committed towards the provision of information, public education and universal access to family planning and reproductive health for all Indonesians, which are part of the Indonesian government’s overall program.
Ashraf Al-Ouf, President Director of Bayer Indonesia said: "Bayer is a Life Science company and we are committed to help people around the world have a better quality of life through our science. Bayer is the market leader for oral contraceptive in Indonesia and we fully support the Indonesian government’s program and effort in revitalizing family planning in the country. In this regard, Bayer collaborates with the Indonesian government to provide information and educate the public – especially the women of Indonesia – about the importance of reproductive health and contraception. When the women of Indonesia make the right and informed choice for their own and their families’ health, they help secure the overall health and wellbeing of the nation."
During a family planning workshop, the Head of BKKBN, dr. Surya Chandra Surapaty, MPH, Ph.D said, "The World Contraception Day celebration is here to remind Indonesians on the importance of family planning. The use of contraception by active and healthy couples in their reproductive age to delay or prevent unwanted pregnancy is a true mental revolution as it determines a family to plan for a better future along with their overall wellbeing and prosperity. The participation of families in the national program for Population, Family Planning and Family Development (KKBPK) is the actualization of the mental revolution that our President proclaims."
Poor reproductive health can negatively affect the next generation. These include when mothers or babies die during delivery. The health of mothers greatly affects the health, growth, development and education of their children.
The total fertility rate – the average children that would be born to a woman over her lifetime – in Sragen has lowered to 2,1% According to the 2010 census, the population of Sragen is at 858,266 with a population growth at 0.05% and total fertility rate (TFR) at 2.25 percent which below to national TFR (2,6 percent). 161,123 couples of reproductive age are registered and they are served by 59 family planning facilities throughout the regency.
-- end –-
About World Contraception Day
The World Contraception Day global campaign is sponsored by Bayer Healthcare in collaboration with global institutions such as Asia Pacific Council on Contraception (APCOC), Centro Latinamericano Salud y Mujer (CELSAM), European Society of European Society of Contraception and Reproductive Health (ESC), Deutsche Stiftung Weltbevoelkerung (DSW), International Federation of Pediatric and Adolescent Gynecology (FIGIJ), International Planned Parenthood Federation (IPPF), Marie Stopes International (MSI), Population Services International (PSI), The Population Council, The United States Agency for International Development (USAID), Women Deliver (WD). Bayer Healthcare’s participation as member-partner is also extended to all countries in which Bayer operates, including in Indonesia, through support to the World Contraception Day initiated by BKKBN along several other professional and governmental institution as partners.
About Bayer Women’s HealthCare
In the field of Women’s Healthcare, Bayer HealthCare is currently concentrating on three areas: contraception, menopause management and gynecological treatments. Bayer is a leading company in the field of female hormonal contraception. Being able to make a conscious decision on whether and when to have children has decisively strengthened women’s role in society. Bayer provides a wide range of short-term, long-term and permanent contraceptive choices for women to meet individual needs. In the area of oral contraception, the "pill" has help women all over the world plan their families for more than 50 years. For women who prefer non-daily contraception, long-term intrauterine contraceptive systems with a duration of action of up to five years are available. In situations in which women have completed their families, Bayer also offers a non-surgical alternative for permanent contraception.
Bayer’s Women’s Healthcare portfolio also includes products that relieve symptoms associated with menopause as well as for the treatment of gynecological conditions. In the gynecological therapy segment, Bayer HealthCare is working to develop new therapeutic options for conditions with a high level of unmet medical need such as uterine fibroids (myomas) and endometriosis, a condition in which endometrial cells grow outside of the uterus. A treatment for endometriosis is available to women in several regions including Asia Pacific.
Bayer HealthCare is committed to research to discover innovative approaches to treat gynecological disorders such as endometriosis and uterine fibroids, and is working on further developing a broad spectrum of contraception options to cater to the individual needs of women throughout the world.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which is to be floated on the stock market as Covestro by mid-2016 at the latest.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20,0 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60,700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.
Head of Corporate Communication PT Bayer Indonesia
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.